Loading organizations...
Heidelberg Epignostix, based in Heidelberg, Germany, develops AI-based bioinformatics algorithms utilizing DNA methylation for precise tumor classification, aiming to improve cancer diagnosis, prognosis, and therapy management. The company's lead product, the Heidelberg Brain Tumor Classifier, is available as a research-use-only tool, initially focused on brain tumors, providing classification services to healthcare professionals, researchers, and pharmaceutical companies. Heidelberg Epignostix recently secured €4.3 million in seed funding, with the round led by CARMA FUND I Capital and participation from High-Tech Gründerfonds, LBBW Venture Capital, and Start-up BW Seed Fonds. Helge Lubenow was appointed CEO in July 2024, succeeding co-founder David Jones, who transitioned to CSO. Co-founder Felix Sahm also remains a key leader. The company was founded in 2022 by David Jones and Felix Sahm.
Heidelberg Epignostix has raised $4.7M across 1 funding round.
Heidelberg Epignostix has raised $4.7M in total across 1 funding round.
Heidelberg Epignostix has raised $4.7M across 1 funding round. Most recently, it raised $4.7M Seed in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 8, 2024 | $4.7M Seed | Carma Fund | — | Announced |
Heidelberg Epignostix has raised $4.7M in total across 1 funding round.
Heidelberg Epignostix's investors include Carma Fund.
